Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Gosogliptin
- DrugBank Accession Number
- DB08382
- Background
Gosogliptin has been used in trials studying the treatment of Renal Insufficiency, Chronic.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Gosogliptin (DB08382)
- Weight
- Average: 366.4089
Monoisotopic: 366.19796583 - Chemical Formula
- C17H24F2N6O
- Synonyms
- 2-(4-{(3S,5S)-5-[(3,3-difluoropyrrolidin-1-yl)carbonyl]pyrrolidin-3-yl}piperazin-1-yl)pyrimidine
- Gosogliptin
- External IDs
- PF-00734200
- PF-734,200
- PF-734200
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism ADipeptidyl peptidase 4 inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcarbose The risk or severity of hypoglycemia can be increased when Acarbose is combined with Gosogliptin. Acebutolol The therapeutic efficacy of Gosogliptin can be increased when used in combination with Acebutolol. Acetazolamide The therapeutic efficacy of Gosogliptin can be increased when used in combination with Acetazolamide. Acetohexamide Gosogliptin may increase the hypoglycemic activities of Acetohexamide. Acetyl sulfisoxazole The therapeutic efficacy of Gosogliptin can be increased when used in combination with Acetyl sulfisoxazole. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acid amides
- Alternative Parents
- N-arylpiperazines / Pyrrolidinecarboxamides / Dialkylarylamines / N-acylpyrrolidines / Aminopyrimidines and derivatives / N-alkylpiperazines / Tertiary carboxylic acid amides / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds show 7 more
- Substituents
- 1,4-diazinane / Alkyl fluoride / Alkyl halide / Alpha-amino acid amide / Amine / Aminopyrimidine / Aromatic heteromonocyclic compound / Azacycle / Carbonyl group / Carboxamide group show 25 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- GI718UO477
- CAS number
- 869490-23-3
- InChI Key
- QWEWGXUTRTXFRF-KBPBESRZSA-N
- InChI
- InChI=1S/C17H24F2N6O/c18-17(19)2-5-25(12-17)15(26)14-10-13(11-22-14)23-6-8-24(9-7-23)16-20-3-1-4-21-16/h1,3-4,13-14,22H,2,5-12H2/t13-,14-/m0/s1
- IUPAC Name
- 2-{4-[(3S,5S)-5-(3,3-difluoropyrrolidine-1-carbonyl)pyrrolidin-3-yl]piperazin-1-yl}pyrimidine
- SMILES
- [H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCC(F)(F)C1)N1CCN(CC1)C1=NC=CC=N1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 11516136
- PubChem Substance
- 99444853
- ChemSpider
- 9690926
- BindingDB
- 50249479
- ChEBI
- 177858
- ChEMBL
- CHEMBL515387
- ZINC
- ZINC000023247686
- PDBe Ligand
- PF2
- Wikipedia
- Gosogliptin
- PDB Entries
- 3f8s
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Completed Treatment Type 2 Diabetes Mellitus 1 somestatus stop reason just information to hide 2 Completed Treatment Type 2 Diabetes Mellitus 2 somestatus stop reason just information to hide 1 Completed Treatment Renal Insufficiency,Chronic 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.33 mg/mL ALOGPS logP 0.17 ALOGPS logP 0.4 Chemaxon logS -2.4 ALOGPS pKa (Strongest Basic) 9.38 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 64.6 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 93.03 m3·mol-1 Chemaxon Polarizability 36.63 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.8873 Caco-2 permeable - 0.6669 P-glycoprotein substrate Substrate 0.648 P-glycoprotein inhibitor I Inhibitor 0.6514 P-glycoprotein inhibitor II Non-inhibitor 0.6933 Renal organic cation transporter Inhibitor 0.5225 CYP450 2C9 substrate Non-substrate 0.8559 CYP450 2D6 substrate Non-substrate 0.6078 CYP450 3A4 substrate Substrate 0.5847 CYP450 1A2 substrate Inhibitor 0.6332 CYP450 2C9 inhibitor Inhibitor 0.5428 CYP450 2D6 inhibitor Non-inhibitor 0.7807 CYP450 2C19 inhibitor Non-inhibitor 0.5508 CYP450 3A4 inhibitor Non-inhibitor 0.6445 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.5971 Ames test Non AMES toxic 0.6791 Carcinogenicity Non-carcinogens 0.9048 Biodegradation Not ready biodegradable 0.9961 Rat acute toxicity 2.6944 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8928 hERG inhibition (predictor II) Inhibitor 0.9126
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-0019000000-8a02289ac56ddaa6e95f Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-014i-0009000000-96316ffa406454ef3fde Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-1029000000-ce90638f41ea43895de1 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-014i-0029000000-54695b21e83e694a56fc Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-01q0-0579000000-9a8eb8dc88e8ecb504bc Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0udi-1937000000-2122a1394d574f5c7793 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 182.04768 predictedDeepCCS 1.0 (2019) [M+H]+ 184.44325 predictedDeepCCS 1.0 (2019) [M+Na]+ 190.35579 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation (PubMed:10900005, PubMed:10951221, PubMed:11772392, PubMed:17287217). Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC (PubMed:10900005, PubMed:10951221, PubMed:11772392, PubMed:14691230). Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner (PubMed:17287217). Its interaction with ADA also regulates lymphocyte-epithelial cell adhesion (PubMed:11772392). In association with FAP is involved in the pericellular proteolysis of the extracellular matrix (ECM), the migration and invasion of endothelial cells into the ECM (PubMed:10593948, PubMed:16651416). May be involved in the promotion of lymphatic endothelial cells adhesion, migration and tube formation (PubMed:18708048). When overexpressed, enhanced cell proliferation, a process inhibited by GPC3 (PubMed:17549790). Acts also as a serine exopeptidase with a dipeptidyl peptidase activity that regulates various physiological processes by cleaving peptides in the circulation, including many chemokines, mitogenic growth factors, neuropeptides and peptide hormones such as brain natriuretic peptide 32 (PubMed:10570924, PubMed:16254193). Removes N-terminal dipeptides sequentially from polypeptides having unsubstituted N-termini provided that the penultimate residue is proline (PubMed:10593948)
- Specific Function
- aminopeptidase activity
- Gene Name
- DPP4
- Uniprot ID
- P27487
- Uniprot Name
- Dipeptidyl peptidase 4
- Molecular Weight
- 88277.935 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Dai H, Johnson SL, Terra SG, Marbury TC, Smith WB, Alcorn H, Boyd RA, Wang R, Nguyen TT: The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency. Br J Clin Pharmacol. 2011 Jul;72(1):85-91. doi: 10.1111/j.1365-2125.2011.03954.x. [Article]
Drug created at September 15, 2010 21:31 / Updated at July 18, 2024 12:20